Dr. Anjie Zheng is an Assistant Professor and Associate Research Fellow at the AoP, XJTLU. His research focuses on lipid-based drug delivery systems, tumor immunology, and translational nanomedicine, especially in the context of hard-to-treat solid tumors such as glioma.

    Dr. Zheng holds extensive experience across academic research, industrial R&D, and clinical pharmacology, having previously contributed to the development of two innovative lipid-based immunotherapeutics:

1. HF1K16 – the world’s first actively loaded ATRA liposomal immunomodulator targeting MDSCs, now under Phase II clinical trials.
2. HF50 – the world’s first clinical-stage lipid-based T-cell engager (TCE) nanomedicine, which obtained clinical approval from the CDE in 2024.

Dr. Zheng was granted with fundings: 

National Natural Science Foundation of China – Youth Project (PI)

China Postdoctoral Science Foundation Special Funding (17th Batch)

Now our group is  actively involved in postgraduate training, undergraduate FYP supervision.